Exxel Pharma to Participate in a 'New to Virtual Investor' Segment
Live moderated video webcast on Wednesday, February 5th at 4:00 PM ET
AURORA, CO / ACCESS Newswire / January 31, 2025 / Exxel Pharma ("Exxel" or the "Company"), a pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal hypersensitivity disorders, today announced that it will participate in a "New to Virtual Investor" segment on Wednesday, February 5, 2025 at 4:00 PM ET.
As part of the event, Soren Mogelsvang, PhD, President and Chief Executive Officer of Exxel Pharma, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A live video webcast will be available on the Investors page of the Company's website (exxelpharma.com). Viewers can also access the event on the Virtual Investor website at virtualinvestorco.com.
About Exxel Pharma
Exxel Pharma is a privately held pharmaceutical company focused on developing innovative therapeutics for neuronal hypersensitivity disorders. The Company's lead program, EX937, is a first-in-class, orally administered, proprietary small molecule designed to specifically and peripherally inhibit the fatty acid amide hydrolase (FAAH) enzyme. Exxel is initiating a first-in-human Phase 1/1b clinical study of EX937 for refractory chronic cough, a significant unmet medical need with no FDA-approved treatments. In preclinical studies, EX937 demonstrated robust efficacy in modulating chronic cough across multiple models. Furthermore, it has shown a favorable safety profile and is designed to avoid central side effects by being entirely excluded from the brain. EX937 also holds promise for a range of high-value indications, including hyperactive bladder, peripheral painful neuropathies, and migraine headaches. In addition to EX937, Exxel Pharma is advancing its ARN compounds, a second lead program targeting social anxiety disorder and autism spectrum disorder.
Investor ContactJenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775E: exxel@jtcir.com
SOURCE: Exxel Pharma, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company
UPPSALA, SE / / June 11, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, has signed a new Master Service Agreement (MSA) - along with an initial Work Order of ~800 kSEK - with a Tier-1 US-based biopharmaceutical company. The new customer, a global leader in oncology drug development, becomes the fifth Tier-1 US biopharma company to join Biovica's Pharma Services customer base. The agreement covers testing of Phase 1 clinical trial samples in support of the development of next-generation CDK4/6 inhibitors and is a pilot study with DiviTum® TKa. " This marks a milestone in our growing customer base, highlighting the increasing relevance of Biovica's TKa biomarker assay in advanced cancer therapy development. It demonstrates the strong and growing recognition of the value our assay brings to the development of next-generation oncology treatments that ultimately benefit cancer patients. ," said Anders Rylander, CEO of Biovica. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments Biovica signs agreement with fifth Tier-1 US biopharma company SOURCE: Biovica International View the original press release on ACCESS Newswire Sign in to access your portfolio
Business Insider
2 hours ago
- Business Insider
Why Is Unicycive Therapeutics Stock (UNCY) Down 35% Today?
Unicycive Therapeutics (UNCY) stock suffered a major setback on Tuesday due to an update from the Food and Drug Administration (FDA). The agency found deficiencies at one of the clinical-stage biopharmaceutical company's third-party manufacturing vendors. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Due to these deficiencies, the FDA has precluded any label discussions surrounding a New Drug Application for oxylanthanum carbonate. This is the company's treatment for hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive Therapeutics expects a final decision from the FDA by June 28, 2025. UNCY stock dropped 35.56% alongside today's news and is down 31.65% year-to-date. Despite this, the shares are still up 37.4% over the past 12 months. Is Unicycive Therapeutics Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Unicycive Therapeutics is Strong Buy, based on six Buy ratings over the last three months. With that comes an average UNCY stock price target of $6.67, representing a potential 1,012.04% upside for the shares.
Yahoo
4 hours ago
- Yahoo
Why Topgolf Callaway Rallied on Monday
An insider bought $2.5 million in Topgolf Callaway stock. Topgolf Callaway's shares have been cut in half over the past year, and the company will execute a spinoff of Topgolf later this year. However, this big insider buy doesn't necessarily mean you should follow into the stock. 10 stocks we like better than Topgolf Callaway Brands › Shares of Topgolf Callaway (NYSE: MODG) rocketed 11.3% higher on Monday, as of 1:16 p.m. ET. The company, which owns the Callaway golf club and ball brand, as well as Topgolf driving range restaurants, rose on a disclosure that an insider purchased a significant amount of stock on the open market last week. With the stock having been cut in half over the past year and 83% off its 2021 all-time highs, investors might have seen the insider buy as a sign the stock is bottoming. On Friday, it was disclosed that director Adebayo Ogunlesi purchased more Topgolf shares on the open market between June 4 and 5 of last week. All in all, Ogunlesi bought 383,701 shares last week, at an average price around $6.47 per share, good for about $2.5 million. The Nigerian-born Ogunlesi has had a storied career as an investment banker, then chairman and managing partner of private equity firm Global Infrastructure Partners. BlackRock bought GIP last year, and Ogunlesi also became a BlackRock board member. Ogunlesi may see the beaten-down shares as a bargain, given that the high inflation of the past couple of years, which dampened demand at Topgolf, may be ebbing. Additionally, Topgolf and Callaway are about to split the company, with management announcing it will spin off 80.1% of Topgolf in late 2025, effectively undoing the 2021 acquisition of Topgolf by Callaway. So, Ogunlesi may be bullish on the financial engineering and prospects for each company as stand-alone entities. Before diving in, investors may want to pause and look closer at the stock. Topgolf is down so much because recent results have been disappointing. So, does Ogunlesi see signs of a reversal in these trends? It should be noted that Ogunlesi has been a Callaway board member since 2010. That means he was part of the decision to buy Topgolf in the first place -- a decision that is now being unwound. Moreover, Ogunlesi last bought shares on the open market in June 2023, and shares are down 60% since that purchase. Therefore, investors should do their own due diligence on this turnaround situation, not just follow this insider into the stock. Before you buy stock in Topgolf Callaway Brands, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Topgolf Callaway Brands wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Billy Duberstein and/or his clients has no position in any of the stocks mentioned. The Motley Fool recommends Topgolf Callaway Brands. The Motley Fool has a disclosure policy. Why Topgolf Callaway Rallied on Monday was originally published by The Motley Fool Sign in to access your portfolio
